Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21

Core Insights - Celldex Therapeutics, Inc. (NASDAQ:CLDX) is identified as a promising small-cap stock with significant upside potential, with Barclays raising its price target from $21 to $24 while maintaining an Equal Weight rating [1] - The company has initiated a global Phase 3 trial for barzolvolimab, targeting adult patients with cold urticaria and symptomatic dermographism, conditions for which no advanced approved therapies currently exist [2][3] Company Developments - The Phase 3 trial, named EMBARQ-ColdU and SD, aims to evaluate the efficacy and safety of barzolvolimab, a humanized monoclonal antibody, in patients who remain symptomatic despite H1 antihistamine treatment [2] - Barzolvolimab is the only drug in development that has shown clinical benefits in a randomized, large, placebo-controlled study, meeting all primary and secondary endpoints with high statistical significance at 12 weeks and sustained through the end of the treatment period at 20 weeks in the Phase 2 study [3] - The initiation of this trial marks the second Phase 3 program for barzolvolimab, with another ongoing Phase 3 trial in chronic spontaneous urticaria (CSU) [4] Company Overview - Celldex Therapeutics, Inc. focuses on developing, manufacturing, and commercializing novel therapeutics for human healthcare, with a pipeline that includes Varlilumab, CDX-1140, CDX-301, and CDX-3379 [4]